GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lipidor AB (OSTO:LIPI) » Definitions » COGS-to-Revenue

Lipidor AB (OSTO:LIPI) COGS-to-Revenue : 0.00 (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Lipidor AB COGS-to-Revenue?

Lipidor AB's Cost of Goods Sold for the three months ended in Jun. 2024 was kr0.00 Mil. Its Revenue for the three months ended in Jun. 2024 was kr0.00 Mil.

Lipidor AB's COGS to Revenue for the three months ended in Jun. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Lipidor AB's Gross Margin % for the three months ended in Jun. 2024 was N/A%.


Lipidor AB COGS-to-Revenue Historical Data

The historical data trend for Lipidor AB's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipidor AB COGS-to-Revenue Chart

Lipidor AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial - - - - -

Lipidor AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lipidor AB COGS-to-Revenue Calculation

Lipidor AB's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0.078
=0.00

Lipidor AB's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lipidor AB  (OSTO:LIPI) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Lipidor AB's Gross Margin % for the three months ended in Jun. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Lipidor AB COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lipidor AB's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipidor AB Business Description

Traded in Other Exchanges
N/A
Address
c/o Ekonomistubben AB, Box 55931, Stockholm, SWE, 102 16
Lipidor AB is a pharmaceutical development company with a pipeline of drug development projects in the preclinical and clinical phases. The company develops drugs for the treatment of skin diseases such as psoriasis, bacterial skin infections, and atopic dermatitis.

Lipidor AB Headlines

No Headlines